Eli Lilly CEO on WHO advising against using remdesivir to treat Covid-19
The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly's arthritis drug baricitinib, in combination with Gilead Sciences' remdesivir, to treat Covid-19 patients. On Thursday, a WHO panel advised doctors against using remdesivir as a treatment for patients hospitalized with Covid-19. David Ricks, Eli Lilly chairman and CEO, joins "Squawk Box" to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео Eli Lilly CEO on WHO advising against using remdesivir to treat Covid-19 канала CNBC Television
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео Eli Lilly CEO on WHO advising against using remdesivir to treat Covid-19 канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
WHO: Remdesivir shouldn't be used for patients hospitalized with COVID 19Remdesivir & SARS-CoV-2 (COVID-19) | Mechanism of Action, Adverse Effects, Anti-Viral PropertiesGravitas: Does Remdesivir work against the Wuhan virus?Hip to be 'Square', and the big game goes cashlessLIVE: House hearing on building an affordable and sustainable food supply chain — 7/15/22Coronavirus Pandemic Update 37: The ACE-2 Receptor - The Doorway to COVID-19 (ACE Inhibitors & ARBs)Why doctors are worried about severe kidney damage in some COVID-19 patientsCoronavirus Update 113: Remdesivir May Not Work for COVID 19Dr. Nandi: Remdesivir availability and side effectsWhy Pizza Hut Fell Behind In The Pizza WarsCoagulation and Clotting in COVID-19 - Disseminated Intravascular Coagulopathy (DIC)Jim Cramer's 'bull market somewhere' handbookTreatment with Tocilizumab for COVID-19Banks are better positioned than 2008; find pockets to invest, says Hightower's Stephanie LinkRemdesivir et apparition de variantsLee Baker: The odds of the Fed reaching their 2% target are slimUne très vilaine histoire : le remdesivirWhat you need to know about Gilead's 'flopped' Remdesivir drug trialTreatment with Remdesivir for COVID-19Jim Cramer previews earnings game plan for the trading week of Oct. 12